The effect of Nano-curcumin supplementation on clinical symptoms and signs, length of hospital stays and inflammation level in moderate acute pancreatitis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100524004010N33

Enrollment

Registered

2021-11-25

Start date

2021-12-31

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate Acute Pancreatitis. Acute pancreatitis

Interventions

Intervention 1: Intervention group: Will take 80 mg of Nano-curcumin daily in the form of two soft gels each contains 40 mg of Nano-curcumin (Product of Exir Nano Sina Company) orally for two weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Having desire to participate in the study Age range of 18-75 Patients with a clinical diagnosis of moderate acute pancreatitis (specifically, a history of acute abdominal pain associated with a greater than threefold elevation of the serum amylase and/or computed tomographic evidence of acute pancreatitis) presenting within 72 hours of onset of pain. Having the ability to intake soft gels orally

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding History of allergy to Curcumin Acute exacerbation of chronic pancreatitis Taking antioxidant supplements such as vitamin C, vitamin E or omega 3 Severe co-morbid illness (liver disease including Cirrhosis and Hepatitis, renal failure (Cl Cr <30)) Active gastrointestinal ulcers Taking anticoagulants such as Heparin, Clopidogrel, Dipyridamole, Warfarin and Ticlopidine

Design outcomes

Primary

Measure	Time frame
Length of hospital stay. Timepoint: Through study completion, an average of two weeks. Method of measurement: Counting the number of admission days in hospital based on medical records.;Serum C-reactive protein level. Timepoint: At the first and the end of the 2nd week of the study. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Secondary

Measure	Time frame
Abdominal pain severity. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Visual analog scale (VAS).;Serum ALT concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum ALT concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum ALK-P concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Creatinine concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Blood Urea Nitrogen (BUN) concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Amylase level. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Lipase level. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.	—

Measure

Time frame

Abdominal pain severity. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Visual analog scale (VAS).;Serum ALT concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum ALT concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum ALK-P concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Creatinine concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Blood Urea Nitrogen (BUN) concentration. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Amylase level. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.;Serum Lipase level. Timepoint: At the beginning and the end of the study (14th day). Method of measurement: Enzymatic method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Shahid Beheshti University of Medical Sciences

a_hekmat2000@yahoo.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026